Shijiazhuang Yiling Pharmaceutical Co,Ltd.
Home - News

The 7th Conference of Integrative Medicine and Vascular Diseases: Protecting tiny blood vessels is to protect heart and brain health

The 7th Conference of Integrative Medicine and Vascular Diseases: Protecting tiny blood vessels is to protect heart and brain health
According to the "China Cardiovascular Disease Report 2018" compiled by the National Cardiovascular Center, the number of patients with cardiovascular and cerebrovascular diseases in China is about 290 million, and the disability rate and mortality rate remain high for a long time. Cause a heavy burden. On September 7th, at the 7th Conference of Integrative Medicine and Vascular Diseases held in Wuhan, Professor Zhang Yun, Academician of the Chinese Academy of Engineering, Professor Wu Yiling, Academician of the Chinese Academy of Engineering, Professor Yang Yuejin from the Chinese Academy of Medical Sciences, and other Chinese and Western medicine experts gathered together. Conduct in-depth academic exchanges on the prevention and treatment of vascular diseases. Experts pointed out at the meeting that protecting tiny blood vessels is to protect the health of the mind and brain.
Academician Wu Yiling: Traditional Chinese medicine for Tongluo protects microvessels
At the main forum of the conference, Academician Wu Yiling pointed out in the academic lecture on the theme of ?°Construction of Threads and Its Guidance in the Prevention and Treatment of Vascular Diseases?±: Through two national 973 projects, it was found that microvessels are the most important organs determining human health. The transportation function of blood is also an important way and place for material exchange, energy metabolism and information regulation between cells and the external environment. Using modern technology observations, microvessels may have a series of pathological changes such as sputum and cross deformity in the environment of hyperlipemia, hypertension, hyperglycemia, etc. If the structure and function of microvessels can be protected, the organs of the heart, brain and the like can be maintained. Blood supply, effective prevention and treatment of coronary heart disease, angina pectoris, myocardial infarction, cerebral infarction and other cardiovascular and cerebrovascular diseases. Therefore, protecting microvessels is the key to improving the efficacy of prevention and treatment of cardiovascular and cerebrovascular diseases.Shijiazhuang Yiling Pharmaceutical Is a listed company,Can be responsible for you.
Academician Wu Yiling emphasized that in the view of Chinese medicine, the choroid system throughout the body is mainly responsible for running blood. The smallest part of the collaterals in the veins is highly consistent with the microvessels of Western medicine. Therefore, the concept of "Sun Luo-microvessel" has become Western medicine studies microvascular disease theory combining points and treatment breakthroughs. A series of innovative traditional Chinese medicines, such as Tongxinluo Capsule, Shensong Yangxin Capsule and Qiqiangxin Capsule, which are developed under the guidance of TCM semester theory, have been proven to protect microvessels through various mechanisms through a number of basic and clinical evidence-based medical studies. It has a significant effect on the treatment of vascular diseases such as cardiovascular and cerebrovascular diseases, arrhythmia and chronic heart failure.
Academician Zhang Yun: Tongxinluo treats patients with subclinical arteriosclerosis for two years, halving the risk of heart and brain events
Evidence-based medicine is the most scientific, objective and authoritative evaluation method for drug efficacy in the world. It has the characteristics of random, controlled, double-blind and multi-center. Academician Zhang Yun, a well-known cardiovascular disease expert, gave an academic report on the theme of "Interpretation of the results of the study of carotid plaques in the application of Tongxinluo" at the conference. He introduced a comprehensive three-level hospital in the United Nations led by him. A clinical evidence-based study of 1212 patients with cervical subclinical arteriosclerosis was screened in 18 provinces. This study demonstrates that the application of Tongxinluo can safely and effectively reduce carotid intima-media thickness, plaque area and vascular remodeling index. The carotid artery is a window of human blood vessels, which is integrated with blood vessels and microvessels throughout the human body. This means that Tongxinluo Capsule can not only stabilize plaques in cardiovascular and microvascular, inhibit plaque formation, but also reverse plaque. Bad effects on the heart and brain.
Academician Zhang Yun pointed out that the study also observed the occurrence of cardiovascular events such as angina pectoris, myocardial infarction and cerebral infarction in patients with subclinical arteriosclerosis after taking Tongxinluo for 2 years. The results showed that the incidence of cardiovascular events in the treatment group plus Tongxinluo was 7.7%, and the incidence of control patients taking only conventional treatments was as high as 13.2%, which means taking 2 Tongxinxin can reduce the risk of nearly half of cardiovascular events. The research paper was published on March 14, 2019 in the international scientific journal "Nature", "Science Report" (influence factor 4.122).
It is reported that the 7th Conference of Integrative Medicine and Vascular Diseases was sponsored by the Chinese Committee of Integrative Medicine, the Committee of Vascular Choroidage, the Hubei Provincial Association of Integrative Medicine, the Hubei Provincial Traditional Chinese Medicine Association, and the Hubei Provincial Hospital of Traditional Chinese Medicine. More than 1,500 experts and scholars in the fields of arrhythmia, chronic heart failure, and diabetes. The conference set up the main forum and the cardiovascular disease forum, cerebrovascular disease forum, diabetes forum and other sub-forums, and opened more than 700 video sub-sites across the country, more than 30,000 first-line clinicians through video conferences, new media platforms Witnessed this annual event in the field of vascular disease.

We continue to learn to absorb domestic advanced production experience, and rely on product quality and after-sales service by users.Shijiazhuang Yiling Pharmaceutical Is a listed company,Can be responsible for you.

Shijiazhuang Yiling Pharmaceutical